Improved control of severe hypoglycemia in patients with malignant insulinomas by peptide receptor radionuclide therapy

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 11, 2011, Pages 3381-3389

  Van Schaik, E ^a   Van Vliet, E I ^a   Feelders, R A ^a   Krenning, E P ^a   Khan, S ^a   Kamp, K ^a   Valkema, R ^a   Van Nederveen, F H ^a   Teunissen, J J M ^a   Kwekkeboom, D J ^a   De Herder, W W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; DIAZOXIDE; FLUOROURACIL; GLUCOSE; INSULIN; KI 67 ANTIGEN; OCTREOTATE LU 177; OCTREOTIDE; PENTETREOTIDE; PENTETREOTIDE IN 111; PROINSULIN; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 2A; STREPTOZOCIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASCITES; BLOOD TOXICITY; BONE METASTASIS; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CLINICAL ARTICLE; COGNITIVE DEFECT; COLLAPSE; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DEATH; DECREASED APPETITE; DETERIORATION; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; HUMAN; HUMAN TISSUE; HYPERINSULINEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC COMA; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULINOMA; LEUKOPENIA; LIVER BIOPSY; LIVER METASTASIS; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; MALE; MALIGNANT INSULINOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; PARAAORTIC LYMPH NODE; PRIORITY JOURNAL; THROMBOCYTOPENIA; UPPER ABDOMINAL PAIN; WEIGHT GAIN;

ADULT; FEMALE; HUMANS; HYPOGLYCEMIA; INDIUM RADIOISOTOPES; INSULINOMA; LUTETIUM; MALE; MIDDLE AGED; OCTREOTIDE; PANCREATIC NEOPLASMS; RADIOISOTOPES; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 80655147354     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-1563     Document Type: Article

References (31)

1. de Herder WW 2004 Insulinoma. Neuroendocrinology 80(Suppl 1):20-22
2. de Herder WW, Niederle B, Scoazec JY, Pauwels S, Kloppel G, Falconi M, Kwekkeboom DJ, Oberg K, Eriksson B, Wiedenmann B, Rindi G, O'Toole D, Ferone D; Frascati Consensus Conference; European Neuroendocrine Tumor Society 2006 Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology 84: 183-188
3. Service FJ 1995 Hypoglycemic disorders. N Engl J Med 332:1144-1152
4. Service FJ 1997 Insulinoma and other islet-cell tumors. Cancer Treat Res 89:335-346
5. Service FJ, Nelson RL 1980 Insulinoma. Compr Ther 6:70-74 (Pubitemid 10122145)
6. Service FJ, Natt N 2000 The prolonged fast. J Clin Endocrinol Metab 85:3973-3974 (Pubitemid 32055336)
7. Arioglu E, Gottlieb NA, Koch CA, Doppman JL, Grey NJ, Gorden P 2000 Natural history of a proinsulin-secreting insulinoma: from symptomatic hypoglycemia to clinical diabetes. J Clin Endocrinol Metab 85:3628-3630
8. Eriksson B, Annibale B, Bajetta E, Mitry E, Pavel M, Platania M, Salazar R, Plöckinger U; Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society 2009 ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: chemotherapy in patients with neuroendocrine tumors. Neuroendocrinology 90:214-219
9. Vezzosi D, Bennet A, Courbon F, Caron P 2008 Short- and longterm somatostatin analogue treatment in patients with hypoglycemia related to endogenous hyperinsulinism. Clin Endocrinol (Oxf) 68:904-911 (Pubitemid 351703950)
10. Bourcier ME, Sherrod A, DiGuardo M, Vinik AI 2009 Successful control of intractable hypoglycemia using rapamycin in an 86-yearold man with a pancreatic insulin-secreting islet cell tumor and metastases. J Clin Endocrinol Metab 94:3157-3162
11. Kulke MH, Bergsland EK, Yao JC 2009 Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med 360:195-197
12. Kwekkeboom DJ, Teunissen JJ, Kam BL, Valkema R, de Herder WW, Krenning EP 2007 Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabelled somatostatin analogues. Hematol Oncol Clin North Am 21:561-573; x
13. Kwekkeboom DJ, Krenning EP, Lebtahi R, Komminoth P, Kos- Kudła B, de Herder WW, Plöckinger U; Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society 2009 ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology 90: 220-226
14. Breeman WA, de Jong M, Kwekkeboom DJ, Valkema R, Bakker WH, Kooij PP, Visser TJ, Krenning EP 2001 Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 28:1421-1429
15. Goode PN, Farndon JR, Anderson J, Johnston ID, Morte JA 1986 Diazoxide in the management of patients with insulinoma. World J Surg 10:586-592 (Pubitemid 16096415)
16. Fajans SS, Floyd Jr JC, Knopf RF, Rull J, Guntsche EM, Conn JW 1966 Benzothiadiazine suppression in insulin release from normal and abnormal islet cell tissue in man. J Clin Invest 45:481-492
17. Fajans SS, Floyd Jr JC, Thiffault CA, Knopf RF, Harrison TS, Conn JW 1968 Further studies on diazoxide suppression of insulin release from abnormal and islet tissue in man. Ann NY Acad Sci 150:261-280
18. Gefel A, Flatau E, Avalon D, Papo J, Loewenthal M 1975 Malignant metastatic insulinoma treated with streptozotocin. Clin Endocrinol (Oxf) 4:461-168
19. Katsilambros N, Rahman YA, Hinz M, Fussgänger R, Schröder KE, Straub K, Pfeiffer EF 1970 Action of streptozotocin on insulin and glucagon responses of rat islets. Horm Metab Res 2:268-270
20. Bertherat J, Tenenbaum F, Perlemoine K, Videau C, Alberini JL, Richard B, Dousset B, Bertagna X, Epelbaum J 2003 Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study. J Clin Endocrinol Metab 88: 5353-5360 (Pubitemid 37455411)
21. Vezzosi D, Bennet A, Rochaix P, Courbon F, Selves J, Pradere B, Buscail L, Susini C, Caron P 2005 Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with OctreoScan scintigraphy and immunostaining with anti-sst2a and anti-sst5 antibodies. Eur J Endocrinol 152:757-767 (Pubitemid 40744545)
22. Portela-Gomes GM, Stridsberg M, Grimelius L, Rorstad O, Janson ET 2007 Differential expression of the five somatostatin receptor subtypes in human benign and malignant insulinomas - predominance of receptor subtype 4. Endocr Pathol 18:79-85 (Pubitemid 47574991)
23. Krentz AJ, Boyle PJ, Macdonald LM, Schade DS 1994 Octreotide: a long-acting inhibitor of endogenous hormone secretion for human metabolic investigations. Metabolism 43:24-31 (Pubitemid 24047101)
24. Stehouwer CD, Lems WF, Fischer HR, Hackeng WH, Naafs MA 1989 Aggravation of hypoglycemia in insulinoma patients by the long-acting somatostin analogue octreotide (Sandostatin) Acta Endocrinol (Copenh) 121:34-40 (Pubitemid 19167528)
25. Pool SE, Krenning EP, Koning GA, van Eijck CH, Teunissen JJ, Kam B, Valkema R, Kwekkeboom DJ, de Jong M 2010 Preclinical and clinical studies of peptide receptor radionuclide therapy. Semin Nucl Med 40:209-218
26. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO, Krenning EP 2008 Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26: 2124-2130
27. 90Y-Edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 28:1652-1659
28. Teunissen JJ, Kwekkeboom DJ, de Jong M, Esser JP, Valkema R, Krenning EP 2005 Peptide receptor radionuclide therapy. Best Pract Res Clin Gastroenterol 19:595-616 (Pubitemid 41447721)
29. Ong GS, Henley DE, Hurley D, Turner JH, Claringbold PG, Fegan PG 2010 Therapies for the medical management of persistent hypoglycemia in two cases of inoperable malignant insulinoma. Eur J Endocrinol 162:1001-1008
30. Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA, Velculescu VE, Diaz Jr LA, Vogelstein B, Kinzler KW, Hruban RH, Papadopoulos N 2011 DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331:1199-1203
31. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group 2011 Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514-523